Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 9/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192750 | 0.83 | KDM4E (0.54) | ACLYNEU3 | |
| SCHEMBL3528076 | 0.83 | NEU3 (0.58) | NEU3PTK2BSMN1; SMN2 | |
| SCHEMBL5322418 | 0.80 | NEU3 (0.58) | NEU3PTK2BSMN1; SMN2 | |
| SCHEMBL4661120 | 0.79 | TRPV1 (0.54) | GLO1ALOX5APFEN1TRPV1 | |
| SCHEMBL4182264 | 0.79 | MCL1 (0.44) | ACLYTRPV1MCL1 | |
| SCHEMBL4186189 | 0.76 | GLO1 (0.54) | GLO1ALOX5APFEN1MCL1 | |
| SCHEMBL4193067 | 0.75 | MCL1 (0.48) | MCL1 | |
| SCHEMBL3526841 | 0.74 | ALDH1A1 (0.60) | ACLYNEU3PTK2BSMN1; SMN2 | |
| SCHEMBL3378362 | 0.74 | KMT2A (0.46) | GLO1ALOX5APFEN1 | |
| SCHEMBL2036137 | 0.73 | RARB (0.51) | ACLYPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | disclosed |
| CN-101128452-B | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA | 2012-11-21 | — | — | CN | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| CN-101128452-A | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA (KR) | 2008-02-20 | — | — | CN | disclosed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | TNKS2 1981/4885ACLY 4113/4885NEU3 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.